Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
Elgersma RC, Coumans RG, Huijbregts T, Menge WM, Joosten JA, Spijker HJ, de Groot FM, van der Lee MM, Ubink R, van den Dobbelsteen DJ, Egging DF, Dokter WH, Verheijden GF, Lemmens JM, Timmers CM, Beusker PH. Elgersma RC, et al. Among authors: timmers cm. Mol Pharm. 2015 Jun 1;12(6):1813-35. doi: 10.1021/mp500781a. Epub 2015 Feb 18. Mol Pharm. 2015. PMID: 25635711
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD. Black J, et al. Among authors: timmers cm. Mol Cancer Ther. 2016 Aug;15(8):1900-9. doi: 10.1158/1535-7163.MCT-16-0163. Epub 2016 Jun 2. Mol Cancer Ther. 2016. PMID: 27256376
A Platform for the Generation of Site-Specific Antibody-Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines.
Coumans RGE, Ariaans GJA, Spijker HJ, Renart Verkerk P, Beusker PH, Kokke BPA, Schouten J, Blomenröhr M, van der Lee MMC, Groothuis PG, Ubink R, Dokter WHA, Timmers CM. Coumans RGE, et al. Among authors: timmers cm. Bioconjug Chem. 2020 Sep 16;31(9):2136-2146. doi: 10.1021/acs.bioconjchem.0c00337. Epub 2020 Aug 25. Bioconjug Chem. 2020. PMID: 32697078
Org 214007-0: a novel non-steroidal selective glucocorticoid receptor modulator with full anti-inflammatory properties and improved therapeutic index.
van Lierop MJ, Alkema W, Laskewitz AJ, Dijkema R, van der Maaden HM, Smit MJ, Plate R, Conti PG, Jans CG, Timmers CM, van Boeckel CA, Lusher SJ, McGuire R, van Schaik RC, de Vlieg J, Smeets RL, Hofstra CL, Boots AM, van Duin M, Ingelse BA, Schoonen WG, Grefhorst A, van Dijk TH, Kuipers F, Dokter WH. van Lierop MJ, et al. Among authors: timmers cm. PLoS One. 2012;7(11):e48385. doi: 10.1371/journal.pone.0048385. Epub 2012 Nov 12. PLoS One. 2012. PMID: 23152771 Free PMC article.
Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263-275) epitope: an MHC anchor variant peptide for immune modulation.
Boots AM, Hubers H, Kouwijzer M, den Hoed-van Zandbrink L, Westrek-Esselink BM, van Doorn C, Stenger R, Bos ES, van Lierop MJ, Verheijden GF, Timmers CM, van Staveren CJ. Boots AM, et al. Among authors: timmers cm. Arthritis Res Ther. 2007;9(4):R71. doi: 10.1186/ar2269. Arthritis Res Ther. 2007. PMID: 17645792 Free PMC article.
Signaling of an allosteric, nanomolar potent, low molecular weight agonist for the follicle-stimulating hormone receptor.
van Koppen CJ, Verbost PM, van de Lagemaat R, Karstens WJ, Loozen HJ, van Achterberg TA, van Amstel MG, Brands JH, van Doornmalen EJ, Wat J, Mulder SJ, Raafs BC, Verkaik S, Hanssen RG, Timmers CM. van Koppen CJ, et al. Among authors: timmers cm. Biochem Pharmacol. 2013 Apr 15;85(8):1162-70. doi: 10.1016/j.bcp.2013.02.001. Epub 2013 Feb 13. Biochem Pharmacol. 2013. PMID: 23415902
22 results